Data Insights

Anti-CEA-CAR-T Cells by Shanghai First Song Therapeutics for Gastric Cancer: Likelihood of Approval

Anti-CEA-CAR-T Cells is under clinical development by Shanghai First Song Therapeutics and currently in Phase I for Gastric Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Anti-CEA-CAR-T Cells in Gastric Cancer

Data Insights

Anti-CEA-CAR-T Cells by Shanghai First Song Therapeutics for Solid Tumor: Likelihood of Approval

Anti-CEA-CAR-T Cells is under clinical development by Shanghai First Song Therapeutics and currently in Phase I for Solid Tumor. According...

Likelihood of Approval and Phase Transition Success Rate Model - Anti-CEA-CAR-T Cells in Solid Tumor

Data Insights

Anti-CEA-CAR-T Cells by Shanghai First Song Therapeutics for Esophageal Cancer: Likelihood of Approval

Anti-CEA-CAR-T Cells is under clinical development by Shanghai First Song Therapeutics and currently in Phase I for Esophageal Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Anti-CEA-CAR-T Cells in Esophageal Cancer

Data Insights

Anti-CEA-CAR-T Cells by Shanghai First Song Therapeutics for Small Intestine Cancer: Likelihood of Approval

Anti-CEA-CAR-T Cells is under clinical development by Shanghai First Song Therapeutics and currently in Phase I for Small Intestine Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - Anti-CEA-CAR-T Cells in Small Intestine Cancer

Data Insights

Anti-CEA-CAR-T Cells by Shanghai First Song Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval

Anti-CEA-CAR-T Cells is under clinical development by Shanghai First Song Therapeutics and currently in Phase I for Metastatic Colorectal Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - Anti-CEA-CAR-T Cells in Metastatic Colorectal Cancer

Data Insights

Anti-CEA-CAR-T Cells by Shanghai First Song Therapeutics for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

Anti-CEA-CAR-T Cells is under clinical development by Shanghai First Song Therapeutics and currently in Phase I for Metastatic Adenocarcinoma of...

Likelihood of Approval and Phase Transition Success Rate Model - Anti-CEA-CAR-T Cells in Metastatic Adenocarcinoma of The Pancreas